Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for cancer. The company's lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is conducting a Phase 3 registration-enabling clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer.
Celcuity operates in the biotechnology sector. Its products are targeted therapies that are designed to disrupt cancer cell signalling pathways and inhibit tumour growth. Celcuity is not part of a larger organisation and does not have any subsidiaries.
Explore CELC share prices and other stocks on eToro.